Quince Therapeutics' Charles Ryan to Depart as President, Last Day Sept 8, 2026

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Quince Therapeutics, Inc., a Delaware corporation (the "Company” or "Seller"), Quince Therapeutics SpA, a company organized under the laws of Italy ("Quince SPA", "Italian Subsidiary") entered into an a

Quince Therapeutics (Nasdaq: QNCX) reported Q2 2026 results and a corporate update. It completed the stock-for-stock acquisition of Orphai, adding inhaled rapamycin LAM-001 to its pipeline. Quince closed a $115M private placement, with up to $83M more via warrants. Cash was $116M at June 30, 2026, funding operations through end-2028. Net loss was $75.5M.

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline

Quince Therapeutics (QNCX) seeks stockholder approval for proposals tied to its May 2026 acquisition of Orphai Therapeutics and a concurrent $115 million PIPE. The company says Series C preferred and warrants could convert into up to 16.6 million new common shares versus 1.0 million currently outstanding, implying major dilution. It also warns non-approval could trigger cash settlement.

Ingram Micro Holding (INGM) raised $357.7M via a 13.1M share offering at $27.25 each. Its share price is down 2.54% in a day and 6.90% in a week, but up 26% YTD. Analysts debate its valuation, with some seeing it as 19% undervalued at a $33.17 fair value, while others suggest it's overvalued at $17.36.

Oracle has initiated another wave of layoffs, with employees receiving termination emails early Monday. The company has raised its fiscal 2026 restructuring plan cost by $700 million to $2.8 billion, following a 13% workforce reduction in the same period. The latest cuts' scale is undisclosed, but severance packages were offered. The layoffs have drawn criticism from staff and sparked social media discussions.